The GLP is committed to full transparency. Download and review our 2019 Annual Report

Analyzing first fecal transplant death: Donor stool wasn’t tested for rare E. coli strain

| | November 6, 2019

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

This spring, a 73-year-old man with a rare blood condition became the first person to die from drug-resistant bacteria found in a fecal transplant. New details about that unprecedented incident emerged on [October 30].

The man was a participant in a clinical trial run at Massachusetts General Hospital and received fecal transplant capsules made in November with fecal material from one stool donor, according to a paper published [October 30] in the New England Journal of Medicine. Tests after the man’s death revealed that material contained a rare type of E. coli bacteria.

MGH scientists started screening for those kinds of bacteria in January. However, the hospital did not test capsules they’d already produced, researchers disclosed.

Related article:  Hope and hype: What ketamine can and can't do for depression

Twenty-one other people also received capsules made with material from the same donor, the NEJM paper said. One other person reported serious side effects, but recovered; several others tested positive for the resistant bacteria but weren’t made sick.

The paper’s publication comes just days before the FDA will hold a Nov. 4 meeting about the safety and regulation of fecal transplants.

Read full, original post: Massachusetts General Hospital oversaw trial that led to the first death from a fecal transplant, a new paper shows

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend